New York, NY / ACCESSWIRE / February 3, 2014 / NovaBay™ Pharmaceuticals, Inc. (NYSE MKT: NBY), a clinical-stage biopharmaceutical company developing topical non-antibiotic anti-microbial products, recently released a patient case study describing its ground breaking investigational Auriclosene Irrigation Solution, which has the potential to make a difference in patients’ lives.
NovaBay has had positive results from its Phase 2 clinical study CL1001 for auriclosene NVC-422) to prevent blockage and encrustation of long-term indwelling urinary catheters and continues to interact with the FDA to move the program forward. In a recent interview with Stock-Sector.com, Dr. Ron Najafi, Ph.D., the Company's Chairman and CEO, stated:
“This is a very straightforward story. Catheter blockage leads to myriad problems. Our investigational product prevents that blockage and could be a significant improvement for those who must use indwelling catheters.”
In fact, thousands of people could benefit. Because of spinal cord injuries, multiple sclerosis, strokes, or other neurogenic bladder conditions, an estimated 74,000 patients in the U.S. that rely on indwelling catheters routinely suffer from blockage and encrustation. Indwelling catheters are also used in nursing homes and hospitals. NovaBay’s product, once on the market, could free them from the worry of blockage and of all the medical problems that can be caused or exacerbated by blockage, from urinary tract infections to autonomic dysreflexia.
About NovaBay Pharmaceuticals - Going Beyond Antibiotics™
NovaBay™ Pharmaceuticals, Inc. (NYSE MKT: NBY) is a clinical-stage biopharmaceutical company focused on addressing the unmet therapeutic needs of the global, topical anti-infective market with its Aganocide compounds, led by auriclosene. Auriclosene is a new chemical entity invented by NovaBay that has a broad spectrum of activity against bacteria, viruses and fungi. Aganocide compounds are based on the human body's natural immune system and the molecules involved in combating infections. Bacterial resistance to Aganocides is highly unlikely, as demonstrated in published studies. Once pathogens penetrate the body's primary defense, the next line of defense is provided by the white blood cells. NovaBay has focused on understanding these molecules generated by the white blood cells and finding ways, by chemical modification, to allow them to be developed as therapeutic products with the potential to treat a wide range of local, non-systemic infections. NovaBay believes that Aganocides will help reduce the rise of antibiotic resistance as they begin to supplant the usage of classic topical antibiotics.
About World Market Media
World Market Media™ is a financial media holding company that owns and operates its branded specialty divisions and manages its strategic network partnerships. World Market Media is expanding its interlinking portfolio of media properties to create a social network that bridges the world’s capital markets and investment communities.
Contact: Editor's Desk | +1 855 459 4685 | [email protected] | www.WorldMarketMedia.com
Disclaimer: This release contains forward-looking statements and opinions, which are based upon management's current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding building shareholder value and the effect that Aganocides may have. The words "look forward," "unlikely," "believe" and "will" are intended to identify these forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in development, clinical trial, regulatory approval, production and marketing of the company's product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company's intellectual property or trade secrets, the company's ability to obtain additional financing as necessary and unanticipated research and development and other costs. Other risks relating to NovaBay and Aganocide compounds, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay's latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading "Risk Factors." The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.